INmune Fundamentals

INMB
 Stock
  

USD 6.91  0.05  0.72%   

INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
INmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).

INmune Price to Earning Analysis

INmune Bio's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
 2010 2021 2022 (projected)
Revenues USD11 K181 K150.84 K
Revenues10.92 K181 K195.29 K
P/E 
 = 
Market Value Per Share 
Earnings Per Share 
More About Price to Earning | All Equity Analysis

Current INmune Bio Price to Earning

    
  (7.51) X  
Most of INmune Bio's fundamental indicators, such as Price to Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Compare to competition

INmune Accumulated Retained Earnings Deficit

Accumulated Retained Earnings Deficit

(65.39 Million)

INmune Bio Accumulated Retained Earnings Deficit are projected to decrease significantly based on the last few years of reporting. The past year's Accumulated Retained Earnings Deficit were at (63.72 Million)
Based on the latest financial disclosure, the price to earning indicator of INmune Bio is roughly -7.5092 times. This is 129.06% lower than that of the Biotechnology sector and 252.32% lower than that of the Health Care industry. The price to earning for all United States stocks is 126.15% higher than that of the company.

INmune Bio Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining INmune Bio's current stock value. Our valuation model uses many indicators to compare INmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across INmune Bio competition to find correlations between indicators driving INmune Bio's intrinsic value. More Info.
INmune Bio is rated third overall in number of shares shorted category among related companies. It is rated third overall in debt to equity category among related companies . The ratio of Number of Shares Shorted to Debt to Equity for INmune Bio is about  4,156,731 . The current year Average Equity is expected to grow to about 74.3 M. Comparative valuation analysis is a catch-all model that can be used if you cannot value INmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for INmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the INmune Bio's earnings, one of the primary drivers of an investment's value.

INmune Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.
INmune Bio is currently under evaluation in net income category among related companies.

INmune Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of INmune Bio from analyzing INmune Bio's financial statements. These drivers represent accounts that assess INmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of INmune Bio's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(831.49 K)(12.44 M)(7.76 M)(12.1 M)(30.34 M)(31.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earnings before Tax(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Free Cash Flow(761.83 K)(2.06 M)(5.38 M)(8.94 M)(28.5 M)(29.25 M)
Invested Capital219.04 K(160.63 K)428.87 K559 K19.5 M21.04 M
Tangible Asset Value1.9 M849.34 K7.96 M24.14 M83.43 M90.02 M
Working Capital1.59 M25.58 K7.06 M22.21 M78.25 M84.42 M

INmune Bio Institutional Holders

Institutional Holdings refers to the ownership stake in INmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of INmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing INmune Bio's value.
Security TypeSharesValue
Yorkbridge Wealth Partners LlcCommon Shares10.4 K64 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K92 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K87 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K106 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K201 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K182 K
Westside Investment Management IncCommon Shares30.2 K187

INmune Fundamentals

About INmune Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Revenues181 K195.3 K
Revenue to Assets 0.001811  0.001954 
Revenue Per Employee18.1 K19.5 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in INmune Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as INmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for analysis

When running INmune Bio price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
124.1 M
Quarterly Revenue Growth YOY
6.0
Return On Assets
(0.19) 
Return On Equity
(0.41) 
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine INmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.